Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385196618> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W4385196618 endingPage "S77" @default.
- W4385196618 startingPage "S77" @default.
- W4385196618 abstract "Background and Aim: Combination of locoregional therapy (LRT) with systemic therapy may improve the outcome and survival of patients with hepatocellular carcinoma (HCC). This study aimed to compare the clinical outcomes and survival of patients with HCC who were treated with LRT with or without tyrosine kinase inhibitors (TKIs). Methods: In a single-center prospective ongoing study, data was analysed for the 81 patients diagnosed with HCC who were treated with either monotherapy (LRT group, n=29, 35.8%) or combination treatment of LRT+TKIs (n=52, 64.1%). LRT included ablative procedures (n=12, (14.8%) and endovascular procedures [TACE=45 (55.5%), TARE = 24(29.6 %)]. Treatment response was assessed using Liver Imaging Reporting and Data System (LIRADS) response. TKIs [Either sorafenib (n=29) or lenvatinib (n=52)] were added as systemic treatment in those with LR-TR viable or LR-TR- equivocal response to LRT at one month. Repeat sessions of LRT were done in each group as per the LIRADS assessment every 3 months. Patients were assessed for overall survival at one year. Results: There was no difference in age (62.31±8.13 Vs 59.55±10.35 years), gender (86.5% Vs 89.6% males), presence of cirrhosis (96.15% Vs 93.1%), and CTP class among two groups. There was no significant difference in extrahepatic disease or portal venous thrombosis in both groups. There was no difference in the repeat LRT sessions done in two groups over one year (N= 38(72.4%) Vs N=16 (56.2%)]. On Kalpan-Meier analysis, overall survival at 12 months was significantly better in patients on LRT+TKI compared to those on LRT alone (N= 40 (77.9%) vs N=15 (52.1%), p=0.01). There were no major adverse events in either group. Conclusion: In patients with HCC, the combination of LRT and TKIs is superior to LRT alone in improving overall survival at one year." @default.
- W4385196618 created "2023-07-25" @default.
- W4385196618 creator A5010134092 @default.
- W4385196618 creator A5019771067 @default.
- W4385196618 creator A5044538545 @default.
- W4385196618 creator A5057961402 @default.
- W4385196618 creator A5066373911 @default.
- W4385196618 creator A5086116099 @default.
- W4385196618 creator A5090656568 @default.
- W4385196618 date "2023-01-01" @default.
- W4385196618 modified "2023-10-16" @default.
- W4385196618 title "Combination of Locoregional Therapy (LRT) And Tyrosine Kinase Inhibitors (TKIS) is superior to LRT alone in improving the overall survival in Hepatocellular Carcinoma" @default.
- W4385196618 doi "https://doi.org/10.1016/j.jceh.2023.07.271" @default.
- W4385196618 hasPublicationYear "2023" @default.
- W4385196618 type Work @default.
- W4385196618 citedByCount "0" @default.
- W4385196618 crossrefType "journal-article" @default.
- W4385196618 hasAuthorship W4385196618A5010134092 @default.
- W4385196618 hasAuthorship W4385196618A5019771067 @default.
- W4385196618 hasAuthorship W4385196618A5044538545 @default.
- W4385196618 hasAuthorship W4385196618A5057961402 @default.
- W4385196618 hasAuthorship W4385196618A5066373911 @default.
- W4385196618 hasAuthorship W4385196618A5086116099 @default.
- W4385196618 hasAuthorship W4385196618A5090656568 @default.
- W4385196618 hasBestOaLocation W43851966181 @default.
- W4385196618 hasConcept C126322002 @default.
- W4385196618 hasConcept C143998085 @default.
- W4385196618 hasConcept C2776264508 @default.
- W4385196618 hasConcept C2777214474 @default.
- W4385196618 hasConcept C2778019345 @default.
- W4385196618 hasConcept C2778695046 @default.
- W4385196618 hasConcept C2778800853 @default.
- W4385196618 hasConcept C71924100 @default.
- W4385196618 hasConcept C90924648 @default.
- W4385196618 hasConceptScore W4385196618C126322002 @default.
- W4385196618 hasConceptScore W4385196618C143998085 @default.
- W4385196618 hasConceptScore W4385196618C2776264508 @default.
- W4385196618 hasConceptScore W4385196618C2777214474 @default.
- W4385196618 hasConceptScore W4385196618C2778019345 @default.
- W4385196618 hasConceptScore W4385196618C2778695046 @default.
- W4385196618 hasConceptScore W4385196618C2778800853 @default.
- W4385196618 hasConceptScore W4385196618C71924100 @default.
- W4385196618 hasConceptScore W4385196618C90924648 @default.
- W4385196618 hasLocation W43851966181 @default.
- W4385196618 hasOpenAccess W4385196618 @default.
- W4385196618 hasPrimaryLocation W43851966181 @default.
- W4385196618 hasRelatedWork W1566214443 @default.
- W4385196618 hasRelatedWork W1967025143 @default.
- W4385196618 hasRelatedWork W2365544605 @default.
- W4385196618 hasRelatedWork W3126304260 @default.
- W4385196618 hasRelatedWork W3133992429 @default.
- W4385196618 hasRelatedWork W3164491560 @default.
- W4385196618 hasRelatedWork W4214929818 @default.
- W4385196618 hasRelatedWork W4226048327 @default.
- W4385196618 hasRelatedWork W4361955616 @default.
- W4385196618 hasRelatedWork W4361955619 @default.
- W4385196618 hasVolume "13" @default.
- W4385196618 isParatext "false" @default.
- W4385196618 isRetracted "false" @default.
- W4385196618 workType "article" @default.